


PHARMACEUTICAL 2019









PHARMACEUTICAL 2019



Zymeworks Inc. Rank 78 of 371



The relative strengths and weaknesses of Zymeworks Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zymeworks Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Zymeworks Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 364% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	204,369
Cost of Goods Sold	0
Intangible Assets	13,630
Liabilities, Current	29,986
Liabilities, Non-Current	0
Other Assets	19,880
Other Compr. Net Income	0
Other Expenses	2,176
Other Liabilities	33,887
Other Net Income	-1,258
Property and Equipment	6,484
Research and Development	56,684
Revenues	53,019
Selling, General and Administrative Expense	29,457

Output Variable	Value in 1000 USD
Assets	244,363
Liabilities	63,873
Expenses	88,317
Stockholders Equity	180,490
Net Income	-36,556
Comprehensive Net Income	-36,556
Economic Capital Ratio	33%